In a report published Monday, Jefferies & Company reiterated its Buy rating on Celldex Therapeutics CLDX, and raised its price target from $7.00 to $9.00.
Jefferies noted, “CLDX presented positive CDX-011 OS data for TNBC+hGPNMB pts in EMERGE with supportive PFS data, potentially enabling a follow-on accelerated PII trial. Encouraging OS data for hGPNMB only also support a favorable long-term outlook in a broader pt population. With the rindo PIII ongoing and a pot'l pivotal CDX-011 prgm in 6-12 mos (pipeline as upside), CLDX is an attractive small-cap biotech play. Reiterate Buy with a new $9 PT.”
Celldex Therapeutics closed on Friday at $5.52.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in